Members Only Content

Subscribe to get full access

Free Preview

The FDA has cleared the single-source Nano.ARC machine, which will be used in tomosynthesis applications (checking for breast cancer). It’s a big step for the company which takes away some risk for investors. This is a major milestone for Nano-X, but much work remains as there are still manufacturing and distribution hurdles to be cleared. We’ll also be talking about Nike and its efforts to go direct-to-consumer which has shut out some major retailers.

related news & insights

  • 7investing logo next to the Upstart logo.
    June 12, 2025||0 min||||

    Upstart Deep Dive: June 2025

    Upstart Recommendation Report Upstart Presentation Slides

  • May 30, 2025||0.8 min||||

    7investing Exclusive: A Deep Dive Into Lemonade

    Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]

  • May 16, 2025||46.1 min||||

    What’s Next for Digital Advertising? 7investing Interviews PubMatic CEO Rajeev Goel

    PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]